Browse the evidence

GLP-1 receptor agonists reduce hospitalizations for heart failure (HHF) by approximately 10-11%, although their effect on heart failure with reduced ejection fraction (HFrEF) is neutral or potentially harmful in small studies.

If you have Type 2 Diabetes and heart failure, GLP-1 RAs can help reduce the risk of being hospitalized for heart failure. However, if you have a specific type of heart failure where the heart muscle is weak (HFrEF), the data is less clear, and you should discuss the risks and benefits with your doctor.

Obesity should be clinically classified as a chronic, progressive, and relapsing disease rather than a lifestyle choice or mere risk factor, which is necessary to combat stigma and promote effective long-term management.

Understand that obesity is a chronic medical condition, not a character flaw. This means it requires long-term management strategies similar to other chronic diseases like hypertension or diabetes, rather than short-term 'fixes' based on willpower. Seek care from providers who view it as a disease to manage, not a failure to overcome.

In healthy humans, disuse-induced muscle atrophy is primarily driven by a significant reduction in muscle protein synthesis (MPS), while muscle protein breakdown (MPB) remains largely unchanged.

If you are immobilized or inactive but healthy, your muscle loss is not because your body is actively destroying muscle tissue, but because it has stopped building it. The primary lever to prevent loss is to restore the stimulus for muscle protein synthesis (e.g., through resistance exercise or adequate protein intake) rather than focusing solely on preventing breakdown.

In disease states (e.g., sepsis, cancer, critical illness), muscle atrophy is driven by both elevated muscle protein breakdown (MPB) and reduced muscle protein synthesis (MPS), mediated by inflammatory cytokines.

If you have a disease involving inflammation (like cancer or sepsis), your muscle loss is driven by both increased breakdown and decreased synthesis due to inflammatory signals. Preventing loss requires addressing the underlying disease and inflammation, not just rest or exercise.

Linoleic acid has a long half-life in the body (approximately two years), meaning that reducing intake takes years to significantly lower tissue levels.

Be patient when reducing seed oils. It can take up to six years to significantly replace body stores of linoleic acid with healthier fats.

Very low-carbohydrate/ketogenic, Paleolithic, and low-carbohydrate dietary patterns have low to moderate or poor alignment with 2021 AHA Dietary Guidance due to restrictions on whole grains, legumes, and oils, and high saturated fat content.

If you follow a low-carb, Paleo, or ketogenic diet, be aware that it may not align well with heart health guidelines. These diets often restrict whole grains, legumes, and healthy oils, and may be high in saturated fat. Consult a registered dietitian to ensure nutrient adequacy and minimize cardiovascular risk.

Ultraprocessed food (UPF) consumption does not have a unique mechanistic link to increased body mass index or obesity risk, as epidemiological associations are weak and mechanistic evidence is lacking or contradictory.

Do not avoid all processed foods based on the NOVA classification. Focus on nutrient density, portion control, and overall dietary patterns. Many processed foods are safe, nutritious, and affordable. Avoiding them entirely may lead to nutrient deficiencies and higher costs without proven health benefits.

Bariatric surgery significantly reduces the overall incidence of cancer, obesity-related cancers, and cancer-associated mortality in patients with morbid obesity compared to conventional treatment.

For individuals with morbid obesity, bariatric surgery is a highly effective intervention for reducing the risk of developing various cancers, particularly obesity-related types like breast, colorectal, and endometrial cancer, as well as reducing cancer mortality. This benefit is attributed to sustained weight loss and metabolic improvements that are difficult to achieve through lifestyle changes alone.

Bariatric surgery significantly reduces the incidence of specific obesity-related cancers, including hepatocellular, colorectal, pancreatic, gallbladder, breast, endometrial, and ovarian cancers.

Bariatric surgery offers significant protection against several specific types of cancer, particularly those linked to obesity and hormones (breast, endometrial, ovarian) and metabolic factors (liver, colorectal, pancreatic, gallbladder).

Produce prescription programs do not significantly change BMI z-score in children, despite improvements in fruit and vegetable intake and food security.

While produce prescription programs improve diet and food security for children, they may not immediately impact BMI z-score. Focus on the overall health benefits and improved access to nutritious food rather than expecting immediate changes in weight metrics.

Lifestyle interventions alone are often insufficient for long-term weight maintenance due to hormonal and metabolic adaptations that drive weight regain, necessitating adjunctive therapies for many patients.

If you regain weight after lifestyle changes, do not blame yourself. Your body's hormones and metabolism are adapting to store energy. This is a common biological response, and it is why medical guidelines recommend considering additional therapies (like medication) if lifestyle changes alone do not sustain your results.

Sulfonylureas are associated with weight gain, hypoglycemia, and declining long-term efficacy, making them unsuitable as first- or second-line treatments.

Avoid sulfonylureas if possible. They cause weight gain and low blood sugar, and their effectiveness fades over time. Use them only if other, safer options are not available or affordable.

Adipose tissue (AT) dysfunction, rather than fat mass alone, is the primary mechanistic link between obesity and adverse health outcomes, explaining why some individuals with obesity remain metabolically healthy while others with normal weight develop obesity-related diseases.

Your health risk from obesity is not just about how much you weigh, but how your fat tissue is functioning. Factors like visceral fat, inflammation, and insulin sensitivity matter more than BMI alone. Focus on metabolic health markers rather than just the scale.

Intermittent Energy Restriction (IER), including intermittent fasting and time-restricted eating, does not provide clear incremental benefit over Continuous Energy Restriction (CER) for weight loss or cardiometabolic health in humans.

Intermittent fasting or time-restricted eating is not superior to simply eating fewer calories every day for weight loss or heart health. If you prefer fasting, it may help you restrict calories, but it offers no extra metabolic benefit over consistent daily calorie control. Choose the approach that fits your lifestyle and allows you to maintain a healthy diet.

Obesity is a neurobehavioral disorder resulting from the interaction of a 'vulnerable brain' (biological dysregulation of homeostatic and hedonic pathways) and an obesogenic food environment, rather than solely a failure of willpower.

If you struggle with obesity, understand that it is not just a lack of willpower. Your brain's biological signaling for hunger and satiety, combined with the modern food environment, creates a 'vulnerable brain' state. Effective management requires addressing both the biological signals (e.g., through medical or behavioral interventions) and the environment (e.g., reducing access to hyper-palatable foods).

Gut peptides such as GLP-1 and PYY, along with vagal afferent signaling, play a critical role in homeostatic appetite suppression and satiety signaling.

Your gut produces hormones like GLP-1 and PYY when you eat, which signal your brain to stop eating. This is a natural biological process. Understanding this can help explain why certain foods or eating patterns might affect your satiety levels.

Higher intake of unprocessed red meat and total meat is associated with a significantly higher incidence of atherosclerotic cardiovascular disease (ASCVD) in older adults, partly mediated by gut microbiota-derived metabolites TMAO, gamma-butyrobetaine, and crotonobetaine.

If you are over 65, be mindful of your red meat consumption. This study links higher intake of unprocessed red meat and total meat to a higher risk of heart disease and stroke. The risk is partly explained by how gut bacteria process compounds in red meat into substances like TMAO. You don't need to eliminate red meat entirely, but balancing it with fish, poultry, and plant-based proteins may help lower your cardiovascular risk.

Intake of fish, poultry, and eggs is not significantly associated with incident atherosclerotic cardiovascular disease (ASCVD) in older adults.

You can likely continue to eat fish, poultry, and eggs without increasing your risk of heart disease or stroke, according to this study of older adults. These foods do not show the same negative association with cardiovascular health that red meat does. Focus on reducing red meat intake while maintaining these other protein sources.

Intensive lifestyle interventions (diet and exercise) alone do not significantly reduce cardiovascular event risk in overweight/obese adults with type 2 diabetes compared to usual care, whereas weight loss achieved through metabolic surgery significantly reduces complications and mortality.

While healthy eating and exercise are important, they might not be enough to protect your heart if you have type 2 diabetes and are overweight. The Look AHEAD study showed that intensive lifestyle changes didn't lower heart attack or stroke risk compared to standard care. However, losing a significant amount of weight (10% or more) did help. For some, metabolic surgery offers the best chance to reduce complications and live longer. Talk to your doctor about combining lifestyle changes with medications or other treatments.

When inequalities in behavioral weight management interventions do exist, they tend to favor 'more advantaged' groups (e.g., older, higher SES, employed) in terms of trial uptake, intervention adherence, and trial attrition.

If you are from a 'less advantaged' background (e.g., lower income, rural, younger), you may face higher barriers to starting or sticking with a weight loss program. This is not a reflection of your ability but of the program's design requiring high personal agency. Seek programs that reduce these barriers.

Approximately half of patients with type 2 diabetes discontinue SGLT-2 inhibitors or GLP-1 receptor agonists within five years, but a significant portion (approx. 25%) reinitiates therapy within one year of discontinuation, suggesting many discontinuations are temporary pauses rather than permanent abandonment.

If you stop your SGLT-2 inhibitor or GLP-1 RA, it doesn't mean you are done with it. About 1 in 4 people restart within a year. This often happens after a hospital stay. If you pause your medication due to illness or surgery, ask your doctor to help you restart it as soon as it is safe, so you don't lose the long-term heart and kidney benefits.

Intensive glucose-lowering strategies significantly increase the risk of severe hypoglycemia compared to standard therapy.

If you are on intensive diabetes treatment to lower your blood sugar significantly, be aware that your risk of severe low blood sugar (hypoglycemia) nearly doubles compared to standard treatment. This risk must be weighed against the benefits for your eyes and kidneys. Regular monitoring and awareness of hypoglycemia symptoms are crucial.

Mitochondrial dynamics, specifically regulated by Drp1-mediated fission, are essential for maintaining muscle stem cell (satellite cell) regenerative competence and metabolic health throughout adult life.

As you age, your muscle stem cells rely on healthy mitochondrial function to repair tissue. While you cannot directly 'dose' Drp1, you can support mitochondrial health through regular physical activity and adequate nutrition, which are known to promote mitochondrial biogenesis and dynamics. This biological maintenance is key to preserving muscle mass and regenerative ability in adulthood.

Pioglitazone improves NASH histology without worsening fibrosis in patients with T2DM and MAFLD, but its use is limited by side effects including weight gain, fluid retention, and potential bladder cancer risk.

Pioglitazone (45mg daily) can improve liver inflammation (NASH) in people with type 2 diabetes and fatty liver without worsening scarring. However, it can cause weight gain, fluid retention, and may increase the risk of bladder cancer in some people. It is not recommended for everyone and should be used with caution, especially if you have a history of heart failure or bladder cancer.